Clinical Trials Browser

Phase 1 × daratumumab × 30 days × Clear all

NCT04108195 2026-03-13

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

Phase 1 Active not recruiting

Multiple Myeloma

NCT06768489 2026-03-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT07082270 2026-02-19

Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Not yet recruiting

Multiple Myeloma